GentiBio, Inc.

AstraZeneca is to work with Quell Therapeutics to develop its Treg cell therapies in two autoimmune disease areas, paying out $85m upfront in a deal which could be worth well over $2bn. The UK pharma

Dualyx is heading towards the clinic with its regulatory T cells (Tregs) candidates, armed with €40m and the backing of several top-tier healthcare investors. The Belgian group's series A fundraising

Biopharma Acquisitions Biopharma merger and acquisition value for the third quarter of 2022 reached $15.4bn from 41 transactions, 21 of which had disclosed values. Four M&A transactions hit or exceede

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Disc Goes Public As Gemini Downshifts F